

**Table 1. Clinical characteristics of the patients and the control group**

	Patients	Control group	p
Number (%)	n=44 (77.1%)	n=13 (22.9%)	
Age (median)	60,5 (35-88)	42,53 (16-67)	p<0,001
Gender (male/female)	24/2 (54,5%/45,5%) 0	6/7 (46,2%/53,8%)	p=0.594
<b>LDH elevation (LDH&gt;220 U/L)</b>	3 (79,5%) 5	2 (15,4%)	
B symptom positivity	1 (43,2%) 9		
ECOG 1/2	38/6 (86,4%/13,6%)		
<b>Stage n (%)</b> I/II/III/IV	8/13/14/9 (13,8%/29,5%/31,8%/20,5%)		
<b>IPI</b> (0/1/2/3/4)	4/10/12/12/6 (9,1%/22,7%/27,3%/27,3%/13,6%)		
<b>Hepatomegaly</b>	6 (13,6%)		
<b>Splenomegaly</b>	1 (25%) 1		
<b>Bone marrow infiltration</b>	4 (9,1%)		
<b>Extra-nodal involvement</b>	8 (18,2%)		
<b>Bulky disease</b>	5 (11,4%)		
<b>Response to primary care treatment</b>			
<b>Partial</b>	4 (9.1%)		

<b>remission</b>			
<b>Complete remission</b>	30 (68,2%)		
<b>Relapse</b>	5 (11,4%)		
<b>Mortality</b>	1 (25%) 1		
<b>The treatment step s/he received I/II/III</b>	38/4/2 (86,4%/9,1%/4,5%)		